Cargando…

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types

Homologous recombination deficiency (HRD) leads to DNA double‐strand breaks and can be exploited by the use of poly (ADP‐ribose) polymerase (PARP) inhibitors to induce synthetic lethality. Extending the original therapeutic concept, the role of HRD is currently being investigated in clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Budczies, Jan, Kluck, Klaus, Beck, Susanne, Ourailidis, Iordanis, Allgäuer, Michael, Menzel, Michael, Kazdal, Daniel, Perkhofer, Lukas, Kleger, Alexander, Schirmacher, Peter, Seufferlein, Thomas, Stenzinger, Albrecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161338/
https://www.ncbi.nlm.nih.gov/pubmed/35384413
http://dx.doi.org/10.1002/cjp2.271
_version_ 1784719462894665728
author Budczies, Jan
Kluck, Klaus
Beck, Susanne
Ourailidis, Iordanis
Allgäuer, Michael
Menzel, Michael
Kazdal, Daniel
Perkhofer, Lukas
Kleger, Alexander
Schirmacher, Peter
Seufferlein, Thomas
Stenzinger, Albrecht
author_facet Budczies, Jan
Kluck, Klaus
Beck, Susanne
Ourailidis, Iordanis
Allgäuer, Michael
Menzel, Michael
Kazdal, Daniel
Perkhofer, Lukas
Kleger, Alexander
Schirmacher, Peter
Seufferlein, Thomas
Stenzinger, Albrecht
author_sort Budczies, Jan
collection PubMed
description Homologous recombination deficiency (HRD) leads to DNA double‐strand breaks and can be exploited by the use of poly (ADP‐ribose) polymerase (PARP) inhibitors to induce synthetic lethality. Extending the original therapeutic concept, the role of HRD is currently being investigated in clinical trials testing immune checkpoint blockers alone or in combination with PARP inhibitors, but the relationship between HRD and immune cell context in cancer is incompletely understood. We analyzed the association between immune cell composition, gene expression, and HRD in 9,041 tumors of 32 solid cancer types from The Cancer Genome Atlas (TCGA). The numbers of genomic scars were quantified by the HRD sum score (HRDsum) including loss of heterozygosity, large‐scale state transitions, and telomeric allelic imbalance. The T‐cell inflamed gene expression profile correlated weakly, but significantly positively, with HRDsum across cancer types (ρ = 0.17). Within individual cancer types, a significantly positive correlation was observed only in breast cancer, ovarian cancer, and four other cancer types, but not in the remaining 26 cancer types. HRDsum and tumor mutational burden (TMB) correlated significantly positively across cancer types (ρ = 0.42) and within 18 cancer types. HRDsum and a proliferation metagene correlated significantly positively across cancer types (ρ = 0.52) and within 20 cancer types. Mismatch repair deficiency and HRD as well as proofreading deficiency showed a high level of exclusivity. High HRD scores were associated with an immunologically activated tumor microenvironment only in a minority of cancer types. Our data favor the combination of genetic markers, complex genomic markers (including HRDsum and TMB), and other molecular markers (including proliferation scores) for a precise and comprehensive read‐out of the tumor biology and an individually tailored treatment.
format Online
Article
Text
id pubmed-9161338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-91613382022-06-04 Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types Budczies, Jan Kluck, Klaus Beck, Susanne Ourailidis, Iordanis Allgäuer, Michael Menzel, Michael Kazdal, Daniel Perkhofer, Lukas Kleger, Alexander Schirmacher, Peter Seufferlein, Thomas Stenzinger, Albrecht J Pathol Clin Res Original Articles Homologous recombination deficiency (HRD) leads to DNA double‐strand breaks and can be exploited by the use of poly (ADP‐ribose) polymerase (PARP) inhibitors to induce synthetic lethality. Extending the original therapeutic concept, the role of HRD is currently being investigated in clinical trials testing immune checkpoint blockers alone or in combination with PARP inhibitors, but the relationship between HRD and immune cell context in cancer is incompletely understood. We analyzed the association between immune cell composition, gene expression, and HRD in 9,041 tumors of 32 solid cancer types from The Cancer Genome Atlas (TCGA). The numbers of genomic scars were quantified by the HRD sum score (HRDsum) including loss of heterozygosity, large‐scale state transitions, and telomeric allelic imbalance. The T‐cell inflamed gene expression profile correlated weakly, but significantly positively, with HRDsum across cancer types (ρ = 0.17). Within individual cancer types, a significantly positive correlation was observed only in breast cancer, ovarian cancer, and four other cancer types, but not in the remaining 26 cancer types. HRDsum and tumor mutational burden (TMB) correlated significantly positively across cancer types (ρ = 0.42) and within 18 cancer types. HRDsum and a proliferation metagene correlated significantly positively across cancer types (ρ = 0.52) and within 20 cancer types. Mismatch repair deficiency and HRD as well as proofreading deficiency showed a high level of exclusivity. High HRD scores were associated with an immunologically activated tumor microenvironment only in a minority of cancer types. Our data favor the combination of genetic markers, complex genomic markers (including HRDsum and TMB), and other molecular markers (including proliferation scores) for a precise and comprehensive read‐out of the tumor biology and an individually tailored treatment. John Wiley & Sons, Inc. 2022-04-05 /pmc/articles/PMC9161338/ /pubmed/35384413 http://dx.doi.org/10.1002/cjp2.271 Text en © 2022 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Budczies, Jan
Kluck, Klaus
Beck, Susanne
Ourailidis, Iordanis
Allgäuer, Michael
Menzel, Michael
Kazdal, Daniel
Perkhofer, Lukas
Kleger, Alexander
Schirmacher, Peter
Seufferlein, Thomas
Stenzinger, Albrecht
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
title Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
title_full Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
title_fullStr Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
title_full_unstemmed Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
title_short Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
title_sort homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161338/
https://www.ncbi.nlm.nih.gov/pubmed/35384413
http://dx.doi.org/10.1002/cjp2.271
work_keys_str_mv AT budcziesjan homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT kluckklaus homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT becksusanne homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT ourailidisiordanis homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT allgauermichael homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT menzelmichael homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT kazdaldaniel homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT perkhoferlukas homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT klegeralexander homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT schirmacherpeter homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT seufferleinthomas homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes
AT stenzingeralbrecht homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes